TransMedics Group, Inc. Stock

Equities

TMDX

US89377M1099

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
127.3 USD -4.05% Intraday chart for TransMedics Group, Inc. +35.22% +61.26%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 402M Sales 2025 * 523M Capitalization 4.19B
Net income 2024 * 27M Net income 2025 * 38M EV / Sales 2024 * 10.9 x
Net Debt 2024 * 195M Net Debt 2025 * 180M EV / Sales 2025 * 8.36 x
P/E ratio 2024 *
163 x
P/E ratio 2025 *
118 x
Employees 584
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.74%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.05%
1 week+35.22%
Current month+35.22%
1 month+49.67%
3 months+44.37%
6 months+109.48%
Current year+61.26%
More quotes
1 week
116.00
Extreme 116
132.96
1 month
82.87
Extreme 82.87
132.96
Current year
69.43
Extreme 69.43
132.96
1 year
36.42
Extreme 36.4201
132.96
3 years
10.00
Extreme 10
132.96
5 years
10.00
Extreme 10
132.96
10 years
10.00
Extreme 10
132.96
More quotes
Managers TitleAgeSince
Founder 55 98-07-31
Director of Finance/CFO 56 15-02-28
Chief Operating Officer 41 23-02-01
Members of the board TitleAgeSince
Chairman 79 10-12-31
Director/Board Member 66 02-12-31
Director/Board Member 68 20-12-31
More insiders
Date Price Change Volume
24-05-07 127.3 -4.05% 917,365
24-05-06 132.6 +3.64% 1,077,011
24-05-03 128 +2.85% 1,543,193
24-05-02 124.4 +5.82% 1,399,812
24-05-01 117.6 +24.93% 4,941,000

Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT

More quotes
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
127.3 USD
Average target price
120.5 USD
Spread / Average Target
-5.33%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW